SGLT2 Inhibitors: New Hope for the Treatment of Acute Myocardial Infarction?

Overview

Journal Am J Cardiovasc Drugs

Specialties Cardiology & Vascular Diseases
Pharmacology

Date 2022 Aug 10

PMID 35947249

Authors

Yu-Jie Wu

Si-Bo Wang

Lian-Sheng Wang

Affiliations

Soon will be listed here.

Abstract

Among all of the new antidiabetic drugs, an increasing number of studies have evaluated the relationship between the sodium-glucose cotransporter 2 inhibitors (SGLT2i) and acute myocardial infarction (AMI). Since SGLT2i like empagliflozin, canagliflozin, and recently, dapagliflozin have shown impressive positive effects in patients with chronic heart failure with reduced ejection fraction (HFrEF), it has increased research interest to explore the cardiac molecular mechanisms underlying the clinical benefits and attracted more attention to the effects of SGLT2i on a series of cardiovascular events. Experimental and clinical data on SGLT2i treatment after AMI is limited. This is a review of the clinical and preclinical effects of SGLT2i, focusing on available data on the effects of SGLT2i in AMI patients with a brief overview of ongoing trials.

Citing Articles

Cardiovascular Therapy Benefits of Novel Antidiabetic Drugs in Patients With Type 2 Diabetes Mellitus Complicated With Cardiovascular Disease: A Network Meta-Analysis.

Shi S, Li X, Chen Y, Li J, Dai Y J Diabetes. 2025; 17(1):e70044.

PMID: 39789833 PMC: 11717902. DOI: 10.1111/1753-0407.70044.

Effect of sodium glucose cotransporter 2 inhibitors on all cause death and rehospitalization for heart failure in patients with acute myocardial infarction.

Xiong B, He L, Zhang A, Ling Z Sci Rep. 2024; 14(1):30148.

PMID: 39627297 PMC: 11615227. DOI: 10.1038/s41598-024-81954-2.

Comparative effects of canagliflozin and sitagliptin in chronically ischemic myocardium.

Sabe S, Harris D, Broadwin M, Xu C, Sabra M, Banerjee D Vessel Plus. 2024; 8.

PMID: 39176133 PMC: 11339913. DOI: 10.20517/2574-1209.2023.95.

Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.

Cai D, Chen Q, Mao L, Xiao T, Wang Y, Gu Q Eur J Clin Pharmacol. 2024; 80(4):613-620.

PMID: 38319348 PMC: 10937750. DOI: 10.1007/s00228-024-03623-7.

Influence and mechanism of sodium-glucose cotransporter-2 inhibitors on the cardiac function: study protocol for a prospective cohort study.

Cao M, Shi F, Yu B, Ma X, Zhang C, Xu L Front Endocrinol (Lausanne). 2023; 14:1199960.

PMID: 37538793 PMC: 10395085. DOI: 10.3389/fendo.2023.1199960.

References

Castro-Dominguez Y, Dharmarajan K, McNamara R . Predicting death after acute myocardial infarction. Trends Cardiovasc Med. 2017; 28(2):102-109. DOI: 10.1016/j.tcm.2017.07.011. View

Virani S, Alonso A, Aparicio H, Benjamin E, Bittencourt M, Callaway C . Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. Circulation. 2021; 143(8):e254-e743. DOI: 10.1161/CIR.0000000000000950. View

Ibanez B, Heusch G, Ovize M, Van de Werf F . Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 2015; 65(14):1454-71. DOI: 10.1016/j.jacc.2015.02.032. View

Wojcik C, Warden B . Mechanisms and Evidence for Heart Failure Benefits from SGLT2 Inhibitors. Curr Cardiol Rep. 2019; 21(10):130. DOI: 10.1007/s11886-019-1219-4. View

McMurray J, Solomon S, Inzucchi S, Kober L, Kosiborod M, Martinez F . Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381(21):1995-2008. DOI: 10.1056/NEJMoa1911303. View

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Lan N, Yeap B, Fegan P, Green G, Rankin J, Dwivedi G . Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes. Int J Cardiovasc Imaging. 2020; 37(2):517-527. DOI: 10.1007/s10554-020-02034-w. View

Tanajak P, Sa-Nguanmoo P, Sivasinprasasn S, Thummasorn S, Siri-Angkul N, Chattipakorn S . Cardioprotection of dapagliflozin and vildagliptin in rats with cardiac ischemia-reperfusion injury. J Endocrinol. 2017; 236(2):69-84. DOI: 10.1530/JOE-17-0457. View

10.

Paolisso P, Bergamaschi L, Santulli G, Gallinoro E, Cesaro A, Gragnano F . Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol. 2022; 21(1):77. PMC: 9107763. DOI: 10.1186/s12933-022-01506-8. View

11.

Oh C, Cho S, Jang J, Kim H, Chun S, Choi M . Cardioprotective Potential of an SGLT2 Inhibitor Against Doxorubicin-Induced Heart Failure. Korean Circ J. 2019; 49(12):1183-1195. PMC: 6875592. DOI: 10.4070/kcj.2019.0180. View

12.

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

13.

Min S, Oh T, Baek S, Lee D, Kim K, Moon J . Degree of ketonaemia and its association with insulin resistance after dapagliflozin treatment in type 2 diabetes. Diabetes Metab. 2017; 44(1):73-76. DOI: 10.1016/j.diabet.2017.09.006. View

14.

Santos-Gallego C, Requena-Ibanez J, Antonio R, Ishikawa K, Watanabe S, Picatoste B . Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. J Am Coll Cardiol. 2019; 73(15):1931-1944. DOI: 10.1016/j.jacc.2019.01.056. View

15.

Shimizu W, Kubota Y, Hoshika Y, Mozawa K, Tara S, Tokita Y . Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial. Cardiovasc Diabetol. 2020; 19(1):148. PMC: 7519555. DOI: 10.1186/s12933-020-01127-z. View

16.

Lauritsen K, Nielsen B, Tolbod L, Johannsen M, Hansen J, Hansen T . SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial. Diabetes. 2020; 70(3):800-808. DOI: 10.2337/db20-0921. View

17.

Oshima H, Miki T, Kuno A, Mizuno M, Sato T, Tanno M . Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats. J Pharmacol Exp Ther. 2018; 368(3):524-534. DOI: 10.1124/jpet.118.253666. View

18.

Verma S, Rawat S, Ho K, Wagg C, Zhang L, Teoh H . Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors. JACC Basic Transl Sci. 2018; 3(5):575-587. PMC: 6234616. DOI: 10.1016/j.jacbts.2018.07.006. View

19.

Gibb A, Hill B . Metabolic Coordination of Physiological and Pathological Cardiac Remodeling. Circ Res. 2018; 123(1):107-128. PMC: 6023588. DOI: 10.1161/CIRCRESAHA.118.312017. View

20.

Eisner D, Caldwell J, Trafford A, Hutchings D . The Control of Diastolic Calcium in the Heart: Basic Mechanisms and Functional Implications. Circ Res. 2020; 126(3):395-412. PMC: 7004450. DOI: 10.1161/CIRCRESAHA.119.315891. View